Plinabulin: Tubulin polymerization inhibitor vascular-disrupting agent oncolytic

Drugs of the Future

Volumn 35, Issue 1, 2010, Pages 11-15

  Ferrer, E ^a   Bolos J ^a   Castaner R ^a  

^a THOMSON REUTERS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYLIDENE 6 [(5 TERT BUTYL 1H IMIDAZOL 4 YL)METHYLENE] 2,5 PIPERAZINEDIONE; COLCHICINE; DOCETAXEL; IRINOTECAN; KPU 2; PACLITAXEL; PLINABULIN; TUBULIN; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD PRESSURE; CANCER PAIN; CLINICAL TRIAL; DEHYDRATION; DRUG BINDING SITE; DRUG DOSE TITRATION; DRUG SAFETY; FATIGUE; FEVER; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOMA; MICROTUBULE ASSEMBLY; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; SIDE EFFECT; SOLID TUMOR; TUMOR BLOOD FLOW; VOMITING;

EID: 84930540337     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.01.1439262     Document Type: Article

References (22)

1. Hayashi, Y., Grodberg, J., Palladino, M. (Nereus Pharmaceuticals, Inc). Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof. EP 1529044, JP 2006511534, WO 2004054498.
2. Palladino, M.A., Lloyd, G.K., Hayashi, Y., Nicholson, B. (Nereus Pharmaceuticals, Inc). Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof. EP 1711487, JP 2007520565, WO 2005077940.
3. Palladino, M., Lloyd, G.K., Hayashi, Y. (Nereus Pharmaceuticals, Inc). Analogs of dehydrophenylahistins and their therapeutic use. EP 1926724, US 2007078138, WO 2007035841.
4. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Thun, M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4): 225-249
5. Smith, B.D., Smith, G.L., Hurria, A., Hortobagyi, G.N., Buchholz, T.A. Future of cancer incidence in the United States: Burdens upon an aging, changing nation. J Clin Oncol 2009, 27(17): 2758-2765
6. Molina, J.R., Yang, P., Cassivi, S.D., Schild, S.E., Adjei, A.A. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83(5): 584-594
7. Gridelli, C., Rossi, A., Maione, P., Rossi, E., Castaldo, V., Sacco, P.C., Colantuoni, G. Vascular disrupting agents: A novel mechanism of action in the battle against non-small cell lung cancer. Oncologist 2009, 14(6): 612-20.
8. Hayashi, Y., Nicholson, B., Tanaka, K., Oda, A., Lloyd, G.K., Palladino, M.A., Kiso, Y. Discovery of new tubulin inhibitors KPU-2 (NPI-2358) and its derivatives based on diketopiperazine structure and their anti-tumor activity. 23rd Med Chem Symp (Nov 24-26, Tsukuba) 2004, Abst 2P-04.
9. Hayashi, Y., Yamazaki, Y., Kiso, Y. et al. Development of vascular disrupting agents based on anti-microtubule diketopiperazine - Synthesis of a photoaffinity probe for tubulin recognition. 25th Med Chem Symp (Nov 29-Dec 1, Nagoya) 2006, Abst 2P-20.
10. Mori, Y., Yamazaki, Y., Yoshida, T. et al. Synthesis and structure-activity relationship of diketopiperazine-type vascular disrupting agents. 27th Med Chem Symp (Nov 26-28, Osaka) 2008, Abst 2P-42.
11. Palladino, M.A. Jr., Borgstrom, P., Deisseroth, A., Nicholson, B., Bahjat, R., Neuteboom, S., Lloyd, G.K. The halimides, a novel family of diketopiperazines with vascular targeting properties. 15th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17-21, Boston) 2003, Abst B20.
12. Nicholson, B., Bahjat, F.R., Borgstrom, P., Neuteboom, S.T.C., Palladino, M.A. Jr., Lloyd, G.K. NPI-2358, a novel diketopiperazine, induces tubulin depolymerization in vitro and tumor vascular collapse in vivo. Proc Am Assoc Cancer Res (AACR) 2004, 45: Abst 5419.
13. Bishop, J., Nicholson, B., Lloyd, G.K., Jordan, M.A., Wilson, L. The antiproliferative mechanism of action of novel microtubule-targeted phenylahistins NPI-2350 and NPI-2358 as compared with colchicine. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst B235.
14. Nicholson, B., Bishop, J., Hayashi, Y. et al. NPI-2358, a novel tumor vascular disrupting agent. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 3428.
15. Lloyd, G.K., Nicholson, B., Neuteboom, S., Marty, J., Mangold, G., Palladino, M.A. Jr. NPI-2358 and NPI-2386: Two new vascular/tubulin modifying agents greatly potentiate standard chemotherapy in xenograft models. 15th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17-21, Boston) 2003, Abst B59.
16. Lloyd, G.K., Wilson, L., Bishop, J. et al. Preclinical profile of NPI-2358, a tumor vascular disrupting agent. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst B4.
17. Neuteboom, S., Medina, E., Palladino, M.A., Spear, M.A., Lloyd, G.K., Nawrocki, S. NPI-2358, a novel tumor vascular disrupting agent potentiates the anti-tumor activity of docetaxel in the non small cell lung cancer model MV522. Eur J Cancer Suppl [20th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (Oct 21-24, Geneva) 2008] 2008, 6(12): Abst 450.
18. Lloyd, G.K., Shen, Y.Y., Bertelsen, L.B., Stodkilde-Jorgensen, H., Nielsen, T., Horsman, M. Utilizing DCE-MRI to monitor the vascular changes induced in a murine cancer model by the novel vascular disrupting drug NPI-2358. Proc Am Assoc Cancer Res (AACR) 2009, 50: Abst 5641.
19. Pilat, M.J., LoRusso, P., Spear, M.A. et al. Phase 1 trial of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors or lymphomas. Proc Am Assoc Cancer Res (AACR) 2009, 50: Abst 3598.
20. Millward, M., Mita, A., Spear, M.A. et al. Phase I trial of NPI-2358 (a novel vascular disrupting agent) plus docetaxel. J Clin Oncol [45th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): Abst 3571.
21. Millward, M., Mainwaring, P., Spear, M.A. et al. Safety and pharmacokinetics of the vascular disrupting agent (VDA) NPI-2358 combined with docetaxel for the treatment of non-small cell lung cancer (NSCLC). J Thorac Oncol [13th World Conf Lung Cancer (July 31-Aug 4, San Francisco) 2009] 2009, 4(9, Suppl. 1): Abst D10.5.
22. Spear, M.A. NPI-2358 (a novel vascular disrupting agent). 11th Int Symp Anti-Angiogenic Agents: Recent Adv Future Directions Basic Clin Cancer Res (Feb 5-7, San Diego) 2009, Abst.